The US government will spend up to $4.9 million to fund research into ibogaine, a psychedelic drug, as a potential treatment for veterans with post-traumatic stress disorder, Health Secretary Robert F. Kennedy Jr. announced Thursday.

The funding comes from the federal health research agency ARPA-H. Kennedy clarified that these awards "do not fund patient treatment or human subject research," meaning the money supports preparatory work for clinical trials rather than direct testing on people.

President Trump had previously allocated $50 million in April for ibogaine research. The Trump administration disclosed in October that it was advancing the first government-funded trials of ibogaine to treat opioid addiction and PTSD.

Mark Cuban Cost Plus Drug Company will develop domestic manufacturing methods for ibogaine. Kennedy said the drug's price would be similar to generic drug prices if it wins approval.

The National Institute of Mental Health opened a $20 million program studying drugs such as ketamine and psilocybin, with award winners expected to be named in summer 2027. ARPA-H will fund a separate ibogaine effort targeting substance-use disorder, with an announcement expected by end-2026.

Investors tracking government biotech funding and psychedelic drug development should monitor announcements of award winners from ARPA-H and the National Institute of Mental Health through 2026 and 2027.